Website
4DMedical LtdTelephone
61.3.9545.5940
Address
700 Swanston Street Level 7 Carlton, Victoria (VIC) 3053
Description
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. It develops pipeline products that may assist physicians to more effectively diagnose and manage patients with lung disease, which includes XV ventilation analysis, ventilation perfusion, contrast free pulmonary angiography, small animal ventilator, and preclinical scanner. The company was founded by Andreas Fouras in December 2012 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.41 - 1.1
Trade Value (12mth)
AU$122,115.00
1 week
-2.06%
1 month
-8.65%
YTD
-33.57%
1 year
-29.1%
All time high
2.98
EPS 3 yr Growth
18.60%
EBITDA Margin
%
Operating Cashflow
-$31m
Free Cash Flow Return
-40.90%
ROIC
-47.70%
Interest Coverage
-167.30
Quick Ratio
1.70
Shares on Issue (Fully Dilluted)
410m
HALO Sector
Technology
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.12
Date | Announcements |
---|---|
20 November 24 |
AGM Presentation and Chair's address
×
AGM Presentation and Chair's address |
20 November 24 |
Results of AGM
×
Results of AGM |
19 November 24 |
4DMedical wins 3 year commercial contract with UCSD Health
×
4DMedical wins 3 year commercial contract with UCSD Health |
15 November 24 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
08 November 24 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
01 November 24 |
Notification regarding unquoted securities - 4DX
×
Notification regarding unquoted securities - 4DX |
31 October 24 |
Quarterly Activity Report and Appendix 4C for Q1 FY2025
×
Quarterly Activity Report and Appendix 4C for Q1 FY2025 |
23 October 24 |
4DMedical wins $1.9m funding for CT VQ clinical studies
×
4DMedical wins $1.9m funding for CT VQ clinical studies |
18 October 24 |
Notice of Annual General Meeting / Proxy Form
×
Notice of Annual General Meeting / Proxy Form |
11 October 24 |
Notification regarding unquoted securities - 4DX
×
Notification regarding unquoted securities - 4DX |
01 October 24 |
Investor Presentation - Philips update
×
Investor Presentation - Philips update |
30 September 24 |
Annual Report
×
Annual Report |
30 September 24 |
Corporate Governance Statement
×
Corporate Governance Statement |
30 September 24 |
Appendix 4G
×
Appendix 4G |
30 September 24 |
Investor briefing - Philips update
×
Investor briefing - Philips update |
27 September 24 |
4DMedical signs Philips reseller agreement for U.S. market
×
4DMedical signs Philips reseller agreement for U.S. market |
24 September 24 |
Notice of AGM Date
×
Notice of AGM Date |
30 August 24 |
Appendix 4E - Preliminary Final Report
×
Appendix 4E - Preliminary Final Report |
30 August 24 |
FY2024 Full year results
×
FY2024 Full year results |
14 August 24 |
Notification of cessation of securities - 4DX
×
Notification of cessation of securities - 4DX |
14 August 24 |
Expiry of options and Appendix 3Y
×
Expiry of options and Appendix 3Y |
02 August 24 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
31 July 24 |
Quarterly Activity Report and Appendix 4C for Q4 FY2024
×
Quarterly Activity Report and Appendix 4C for Q4 FY2024 |
11 July 24 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
08 July 24 |
4DMedical expands with Jones Radiology contract
×
4DMedical expands with Jones Radiology contract |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.